Nuo Therapeutics, Inc. announced its Annual Meeting of Stockholders for December 16, 2025 at 9 a.m. CST at its Houston headquarters. Stockholders of record at the close of business on October 27, 2025 may vote; there were 48,077,745 shares outstanding on the record date.
Three items are up for vote: elect four directors (David E. Jorden, Paul D. Mintz, Scott M. Pittman, and C. Eric Winzer), ratify MaloneBailey LLP as independent auditor for 2025, and an advisory “say‑on‑pay” vote on named executive officer compensation. The Board recommends voting FOR all proposals, with directors elected by plurality and Proposal 2 and 3 by majority of shares present and entitled to vote.
The proxy notes MaloneBailey has served since June 7, 2024; Marcum LLP was dismissed the same day. Marcum’s prior reports included going concern explanatory paragraphs and the company identified material weaknesses tied to limited accounting resources. Director compensation resumed in 2024–2025, and effective October 1, 2025 base salaries increased to $325,000 for the CEO/CFO and $290,000 for the CSOO. Principal holders include Charles E. Sheedy 24.1% and Scott M. Pittman 11.6%.
Nuo Therapeutics, Inc. reported two governance actions: the board approved salary increases for its top executives and set the date for the 2025 Annual Meeting of Stockholders. Effective October 1, 2025, the salary for Chief Executive and Financial Officer David E. Jorden is $325,000 and the salary for Chief Scientific and Operating Officer Peter A. Clausen is $290,000. The board said the Committee considered an improvement in the company’s business and financial condition in 2025 when approving the increases.
The board fixed the Annual Meeting to be held at the company’s principal executive office on December 16, 2025. Stockholder proposals and director nominations for inclusion in the proxy materials must be received by the company’s Secretary by the close of business on October 20, 2025 and must comply with the company’s By-Laws and SEC rules.